



Molecular Insights into Osteosarcoma

Guest Editors:

Dr. Fan Shen

Department of Laboratory
Medicine and Pathology,
University of Alberta, Edmonton,
AB T6G 2B7, Canada

Prof. Dr. Consolato M. Sergi

1. Children's Hospital of Eastern
Ontario (CHEO), University of
Ottawa, Ottawa, ON K1H 8L1,
Canada
2. Department of Laboratory
Medicine and Pathology,
University of Alberta, Edmonton,
AB T6G 2R3, Canada

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editors

Dear Colleagues,

The quote "Cellular pathology is not an end if one cannot see any alteration in the cell. Chemistry brings the clarification of living processes nearer than does anatomy. Each anatomical change must have been preceded by a chemical one." as stated by Rudolf Virchow (Coper, H., Herken, H., 1963. Dtsch. Med. Wochenschr. 88, 2025–2036). Osteosarcoma is a comparatively painstaking topic for many paediatricians, paediatric surgeons, and paediatric pathologists, because despite progress in numerous paediatric malignancies, the outcomes of the affected individuals are still quite poor.

We would be very grateful to gather basic science articles and clinical reports for this Special Issue, which concentrates on the molecular insights of osteosarcoma. As Virchow stated, a chemical change is the basis of what the pathologists sees under the microscope and the physician can assess clinically. We hope to receive several contributions that may attract the attention of funders and charities in promoting more research in the relatively poorly explored field of pre-cancerous bone histology.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)